Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results.
Adult
Aortic Dissection
/ etiology
Angioplasty, Balloon
/ adverse effects
Coated Materials, Biocompatible
/ adverse effects
Female
Femoral Artery
/ surgery
Humans
Male
Middle Aged
Peripheral Arterial Disease
/ surgery
Popliteal Artery
/ surgery
Postoperative Complications
/ etiology
Prospective Studies
Reoperation
/ statistics & numerical data
Stents
/ adverse effects
Treatment Outcome
Vascular Patency
Angioplasty
Dissection
Peripheral artery disease
Proximal popliteal artery
Superficial femoral artery
Tack
Journal
Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
25
09
2019
accepted:
25
01
2020
pubmed:
18
5
2020
medline:
13
3
2021
entrez:
17
5
2020
Statut:
ppublish
Résumé
The Tack Endovascular System (Intact Vascular, Wayne, Pa) combines low-metallic content with focal delivery to seal areas of dissection associated with balloon angioplasty. The device system is designed to treat vascular dissections in the superficial femoral and proximal popliteal arteries. Tack implants exert low radial force and are associated with minimal metal burden, which reduces the mechanical stress on the arterial wall in treating dissections after balloon angioplasty. This study investigated the safety and effectiveness of the Tack Endovascular System in patients with dissections after drug-coated balloon (DCB) angioplasty. The Tack Optimized Balloon Angioplasty III (TOBA III) study is a prospective, multicenter, single-arm study in which patients who underwent percutaneous transluminal angioplasty with the Medtronic IN.PACT Admiral DCB (Medtronic, Dublin, Ireland) and experienced dissection after angioplasty were treated with Tack implants. The primary end points were freedom from major adverse events at 30 days and primary patency at 12 months. A total of 201 patients were enrolled in the trial, 169 with standard-length lesions (≥20 mm and ≤150 mm) and 32 with long-length lesions (>150 mm and ≤250 mm). Safety and effectiveness results were favorable compared with historical benchmarks at 12 months in the standard-lesion cohort. Notably, patients in the standard-lesion cohort experienced 95.0% primary patency, 97.5% freedom from clinically driven target lesion revascularization, 100% freedom from amputation, and 100% survival at 12 months (P < .0001). Primary patency in long-lesion patients was 89.3%, freedom from clinically driven target lesion revascularization was 96.8%, and freedom from amputation was 100% at 12 months. Device success was achieved in 95.8% (182/190) and 97.7% (43/44) of devices deployed into standard-lesion and long-lesion patients, respectively. Procedural success was 99.4% (168/169) and 100% (44/44) in the standard-lesion and long-lesion cohorts, respectively, with only one bailout stent placed in the entire population. The Tack Endovascular System is a safe and effective treatment option for patients with dissections after angioplasty in the superficial femoral and proximal popliteal arteries, with high patency, low rates of secondary intervention, and low incidence of bailout stenting when it is used in combination with DCB.
Identifiants
pubmed: 32414527
pii: S0741-5214(20)30330-X
doi: 10.1016/j.jvs.2020.01.078
pii:
doi:
Substances chimiques
Coated Materials, Biocompatible
0
Banques de données
ClinicalTrials.gov
['NCT02802306']
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1636-1647.e1Informations de copyright
Copyright © 2020. Published by Elsevier Inc.